Tocilizumab Shortage Prompts US FDA To Loosen CAR-T REMS Requirements

Tocilizumab
US FDA modifies REMS mandating tocilizumab availability for CAR-T cell treatment • Source: Alamy

More from Drug Safety

More from Pink Sheet